215 related articles for article (PubMed ID: 35989066)
1. Clinical Characteristics and Long-term Outcomes in Diabetic Macular Edema Patients: With or without Additional Injection Following Ranibizumab Loading.
Yoon K; Kim ES; Yu SY; Kim K
Korean J Ophthalmol; 2022 Oct; 36(5):398-406. PubMed ID: 35989066
[TBL] [Abstract][Full Text] [Related]
2. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
James DGP; Mitkute D; Porter G; Vayalambrone D
Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Ranibizumab in Diabetic Macular Edema: Long-Term Outcomes.
Zucchiatti I; Bandello F
Dev Ophthalmol; 2017; 60():63-70. PubMed ID: 28427066
[TBL] [Abstract][Full Text] [Related]
4. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol.
Kaya M; Atas F; Kocak N; Ozturk T; Ayhan Z; Kaynak S
Curr Eye Res; 2023 May; 48(5):498-505. PubMed ID: 36629472
[TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation.
Wang XN; Cai X; He S; Zhang X; Wu Q
Int Ophthalmol; 2023 Dec; 43(12):4399-4407. PubMed ID: 33783677
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.
Isik P; Sizmaz S; Esen E; Uysal A; Demircan N
Int Ophthalmol; 2023 Nov; 43(11):4171-4180. PubMed ID: 37505290
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
[TBL] [Abstract][Full Text] [Related]
10. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
[TBL] [Abstract][Full Text] [Related]
11. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
Tsai MJ; Hsieh YT; Peng YJ
Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME).
Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Guthux F; Blin P; Grelaud A
Ophthalmic Res; 2021; 64(4):577-586. PubMed ID: 32932257
[TBL] [Abstract][Full Text] [Related]
14. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
15. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
[No Abstract] [Full Text] [Related]
16. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
17. Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema.
Yigit K; Inan ÜÜ; Inan S; Dogan M; Yavas GF; Cetinkaya E
Int Ophthalmol; 2021 Apr; 41(4):1487-1501. PubMed ID: 33486648
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
19. Association between the patterns of diabetic macular edema and photoreceptors' response after intravitreal ranibizumab treatment: a spectral-domain optical coherence tomography study.
Chatziralli I; Theodossiadis G; Dimitriou E; Kazantzis D; Theodossiadis P
Int Ophthalmol; 2020 Oct; 40(10):2441-2448. PubMed ID: 32424527
[TBL] [Abstract][Full Text] [Related]
20. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
